What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2023-02-14 compared with 2022-11-14 · 31 added, 29 removed, 4 unchanged (94% of the section changed)

Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our common stock.

we fail to maintain the continued listing requirements of Nasdaq, including maintaining the minimum closing bid price requirement, Nasdaq

will take steps to de-list our common stock.

As a result of several factors, including but not limited to recent market sentiment concerning

our industry, the ongoing outbreak of COVID-19 and its effects on the global marketplace, recent volatility in the financial markets generally

due to the expectation of a tightening in monetary policy by the U.S.

Federal Reserve and other geopolitical events, the per share price

of our common stock has declined below the minimum bid price threshold required for continued listing.

Such a de-listing would likely

have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish

to do so, as well as adversely affect our ability to issue additional securities and obtain additional financing in the future.

On November 9, 2022, we received a deficiency notice from Nasdaq (the

“Deficiency Notice”) informing us that our common stock had failed to comply with the $1.00 minimum bid price required for

continued listing under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”) based upon the closing bid price of our common

stock for the 30 consecutive business days prior to the date of the Deficiency Notice.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A),

we have been given 180 calendar days from September 9, 2022, or until May 8, 2023, to regain compliance with Rule 5550(a)(2).

time before May 8, 2023 the bid price of our common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days,

Nasdaq will provide us with written confirmation that we have regained compliance.

If we do not regain compliance with Rule 5550(a)(2) by May 8, 2023,

we may be afforded a second 180 calendar day period to regain compliance.

To qualify, we would be required to meet the continued listing

requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for

the minimum bid price requirement.

In addition, we would be required to notify Nasdaq of our intent to cure the deficiency during the

second compliance period.

the event of a de-listing or threatened de-listing, we would take actions to restore our compliance with Nasdaq Marketplace Rules, but

we can provide no assurances that the listing of our common stock would be restored, that our common stock will remain above the Nasdaq

minimum bid price requirement or that we otherwise will remain in compliance with the Nasdaq Marketplace Rules.

Our failure to meet

the continued listing requirements of Nasdaq Stock Market (“Nasdaq”) could result in a de-listing of our common stock.

we fail to maintain the continued listing requirements of Nasdaq, including maintaining the minimum closing bid price requirement of $1.00

per share, Nasdaq will take steps to de-list our common stock.

As a result of several factors, including but not limited to recent market

sentiment concerning our industry, the ongoing COVID-19 epidemic and its effects on the global marketplace, recent volatility in the financial

markets generally due to the expectation of a tightening in monetary policy by the U.S.

Federal Reserve and other geopolitical events,

the per share price of our common stock has declined below the minimum bid price threshold required for continued listing.

be delisted from Nasdaq, such a de-listing would likely have a negative effect on the price of our common stock and would impair your

ability to sell or purchase our common stock when you wish to do so, as well as adversely affect our ability to issue additional securities

and obtain additional financing in the future.

November 9, 2022, we received a deficiency notice from Nasdaq (the “Deficiency Notice”) informing us that our common stock

had failed to comply with the $1.00 minimum bid price required for continued listing under Nasdaq Listing Rule 5550(a)(1) (“Rule

5550(a)(1)”) based upon the closing bid price of our common stock for the 30 consecutive business days prior to the date of the

Deficiency Notice.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been given 180 calendar days from September 9, 2022,

or until May 8, 2023, to regain compliance with Rule 5550(a)(1).

Thus, if at any time before May 8, 2023 the bid price of our common stock

closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide us with written confirmation that

we have regained compliance.

If we do not regain compliance

with Rule 5550(a)(1) by May 8, 2023, we may be afforded a second 180 calendar day period to regain compliance.

To qualify, we would be

required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for

the Nasdaq, except for the minimum bid price requirement.

In addition, we would be required to notify Nasdaq of our intent and plan to

cure the deficiency during the second compliance period.

the event of a de-listing or threatened de-listing, we would take actions to restore our compliance with Nasdaq Rules, but we can provide

no assurances that the listing of our common stock would be restored, that our common stock will remain above the Nasdaq minimum bid price

requirement or that we otherwise will remain in compliance with the Nasdaq Rules.

RECENT SALES OF UNREGISTERED EQUITY SECURITIES

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors